Wang allegedly manipulated research data by fabricating and falsifying scientific data in grant applications made to the National Institutes of Health. This involved manipulating or adding to images of Western blots, a laboratory method used to identify proteins, in order to bolster evidence and secure grants. Wang may have also lied to scientific journals to substantiate his research.
Simufilam's clinical trial is currently in a late stage, with 735 patients participating as of May 2024. The trial is evaluating the safety and efficacy of the experimental drug in slowing cognitive and functional decline in older adults with mild-to-moderate Alzheimer's disease2.
Hoau-Yan Wang was indicted for one count of fraud against the United States, two counts of wire fraud, and one count of false statements2. The charges are related to the alleged fabrication of research images and data, which Wang may have used to secure federal grants from the National Institutes of Health4.